Episode 49: AI in Pharma / Biotech

Send us Fan Mail

In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data, and how the industry has transitioned from a "serendipity-based" model to one of predictive, generative biology.

We break down the leaders of this revolution, comparing the "TechBio" pioneers like Insilico and Recursion with the massive infrastructure bets currently being made by Big Pharma giants. From the rise of autonomous, "closed-loop" labs to significant improvements in target discovery and preclinical timelines, we analyze where the technology is delivering measurable wins and where the "dirty data" gap still holds the industry back.

Finally, we address the hard truths of this transition, including the recent wave of industry layoffs and the emergence of the "Scientific Translator" as the most vital role in the modern lab. We look ahead to a 2030 landscape defined by digital control arms and personalized medicine, offering essential lessons for any professional navigating the risks and rewards of an AI-integrated pipeline.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#Biotech #AI #Pharma #LifeSciences #Podcast #PetriDishPerspectives

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.